Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 25, 2023, Penumbra, Inc. (NYSE: PEN) announced its participation in two upcoming investor conferences:
- Bank of America Securities 2023 Health Care ConferenceDate: May 9, 2023Time: 1:40 PM ET / 10:40 AM PT
- 2023 RBC Capital Markets Global Healthcare ConferenceDate: May 16, 2023Time: 11:30 AM ET / 8:30 AM PT
Webcasts of these presentations will be accessible on Penumbra's investor relations website for at least two weeks post-event. With its headquarters in Alameda, California, Penumbra focuses on innovative therapies and has a diverse product portfolio addressing substantial medical needs in over 100 countries.